Texas Standard: Ask a doctor: Is it safe to get a haircut, and other questions answered
May 8, 2020
Dr. Fred Campbell, General and Hospital Medicine, answers listeners’ questions about their health during the coronavirus pandemic. Listen to the Q&A.
KSAT 12: Your coronavirus questions answered
May 7, 2020
Dr. Ruth Berggren, infectious diseases specialist and director of the Center for Medical Humanities and Ethics, answers coronavirus questions submitted by viewers. Dr. Berggren discusses restaurants, hair salons and gyms reopening, antibody testing, improvement of testing with increased capacity and more. Watch the interview.
KTSA: Dr. Thomas Patterson discusses clinical trial of new anti-viral drug for COVID-19 patients
May 7, 2020
Dr. Thomas Patterson, chief of the Division of Infectious Disease, was a guest on KTSA’s Jack Riccardi Show. Dr. Patterson discussed the new anti-viral drug, remdesivir, for the sickest COVID-19 patients. Dr. Patterson is leading a local study site in the clinical trial testing the drug, which just received emergency authorization from the FDA. He […]
KTSA: COVID-19 questions answered
May 7, 2020
Dr. Fred Campbell, an internal medicine doctor in the Department of General and Hospital Medicine, answered questions about COVID-19 on KTSA’s Jack Riccardi Show. Topics included low oxygen saturation, lung condition of COVID-19 survivors and antibody treatments. Listen below:
Houston Chronicle: UT Health San Antonio researchers study antibodies against coronavirus
May 6, 2020
SARS-CoV-2 survivors have an important asset: antibodies against it. Studying samples from these individuals will help a team at the Long School of Medicine to understand which antibodies best neutralize the coronavirus. This will be important in developing an effective vaccine against the infection. Read the full story.
KTSA: FDA approves emergency use of COVID-19 drug being tested in San Antonio
May 6, 2020
Dr. Thomas Patterson, chief of the Division of Infectious Diseases, explained the implications of the FDA fast-tracking emergency authorization of the new anti-viral drug, remdesivir. Listen to the interview.